By Dhirendra Tripathi
Investing.com – Sanofi (PA:SASY) (NASDAQ:SNY) ADRs traded 2.5% lower in premarket Monday after an experimental cancer medicine failed to slow progression of a common type of breast cancer.
The patients who got the drug, rather than endocrine treatment, didn’t live longer without the disease progressing, according to Sanofi.
Oral pill amcenestrant was one of six “potentially transformative” products Sanofi has touted and prioritized and was seen as the French drugmaker’s next blockbuster.
Hopes were also high from the drug, given most of the alternatives in the market are painful shots.
The disappointing result doesn’t mean it’s the end of the road for amcenestrant, but it increases the risk of failure for the other trials, according to analysts at Bloomberg Intelligence.
In the Phase II trial, the patients had advanced disease and few treatment options remaining, and the medicine wasn’t combined with another as is often the case in cancer. The company said it would press ahead with other trials.
Other trials of the drug include one called AMEERA-5, an advanced study in which it’s combined with Pfizer’s IBRANCE as a first line treatment of breast cancer that has spread.